Los Angeles Capital Management LLC Increases Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Los Angeles Capital Management LLC lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 639.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 420,748 shares of the company's stock after purchasing an additional 363,863 shares during the quarter. Los Angeles Capital Management LLC owned 0.42% of Neurocrine Biosciences worth $48,479,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. 1832 Asset Management L.P. raised its stake in shares of Neurocrine Biosciences by 1,370.7% in the 2nd quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company's stock valued at $74,507,000 after purchasing an additional 504,400 shares during the period. AQR Capital Management LLC lifted its stake in Neurocrine Biosciences by 23.0% in the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company's stock valued at $166,959,000 after acquiring an additional 228,444 shares in the last quarter. Vanguard Group Inc. boosted its position in Neurocrine Biosciences by 2.3% during the 1st quarter. Vanguard Group Inc. now owns 9,930,926 shares of the company's stock worth $1,369,673,000 after acquiring an additional 220,598 shares during the last quarter. Iron Triangle Partners LP acquired a new stake in shares of Neurocrine Biosciences in the first quarter valued at approximately $30,342,000. Finally, Renaissance Technologies LLC lifted its position in shares of Neurocrine Biosciences by 9.6% in the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company's stock worth $339,790,000 after purchasing an additional 216,500 shares in the last quarter. Institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Stock Up 1.4 %

Shares of NBIX stock traded up $1.76 during trading hours on Friday, reaching $125.74. The company's stock had a trading volume of 561,776 shares, compared to its average volume of 961,480. The company has a market capitalization of $12.73 billion, a price-to-earnings ratio of 33.71 and a beta of 0.35. Neurocrine Biosciences, Inc. has a fifty-two week low of $103.63 and a fifty-two week high of $157.98. The firm's 50 day simple moving average is $118.43 and its 200-day simple moving average is $133.11.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 7,143 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $150.10, for a total value of $1,072,164.30. Following the completion of the transaction, the insider now directly owns 2,507 shares in the company, valued at approximately $376,300.70. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director William H. Rastetter sold 14,250 shares of the company's stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the sale, the director now directly owns 37,491 shares of the company's stock, valued at approximately $5,499,554.79. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Ingrid Delaet sold 7,143 shares of the company's stock in a transaction on Tuesday, August 13th. The shares were sold at an average price of $150.10, for a total transaction of $1,072,164.30. Following the sale, the insider now directly owns 2,507 shares in the company, valued at $376,300.70. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 47,063 shares of company stock worth $7,023,330 in the last three months. 4.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on NBIX. Jefferies Financial Group lifted their price target on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the company a "buy" rating in a research note on Monday, August 19th. BMO Capital Markets reduced their price target on Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating for the company in a research report on Thursday, October 17th. Citigroup boosted their price target on Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a "neutral" rating in a research report on Friday, August 2nd. JPMorgan Chase & Co. boosted their target price on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an "overweight" rating in a report on Wednesday, August 7th. Finally, Guggenheim increased their price target on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.